Medline ® Abstract for Reference 42
of 'Treatment of nocardiosis'
Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients.
Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML
Antimicrob Agents Chemother. 2006;50(4):1599.
We assessed the toxicity and clinical outcomes associated with linezolid therapy (mean duration, 29+/-28 days; range, 8 to 185 days) in 44 patients with serious gram-positive infections. Although a clinical cure was achieved in 73% of the cases, 28/44 (64%) had adverse reactions (thrombocytopenia, n=13; anemia, n=7; gastrointestinal, n=12; peripheral neuropathy, n=1; serotonin syndrome, n=1), such that a systematic monitoring protocol was developed.
Infectious Diseases Department, Austin Health, Studley Rd., Heidelberg, Victoria 3084, Australia. Emma.Bishop@austin.org.au